Home / Stocks / Insecticides (i) Ltd
INSECTICID

Insecticides (i) Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹538.3

Change

-6.8 (-1.25%)

Open

₹545.1

Prev. Close

₹545.1

Day High

₹545.85

Day Low

₹536.0

Volume Analysis

Traded

62,517

Delivered

56,908

Delivery %

91.03%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (30.9%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹553.95 ₹549.9 ₹544.1 ₹540.05 ₹534.25 ₹530.2 ₹524.4
Fibonacci ₹549.9 ₹546.14 ₹543.81 ₹540.05 ₹536.29 ₹533.96 ₹530.2
Camarilla ₹541.01 ₹540.11 ₹539.2 ₹540.05 ₹537.4 ₹536.49 ₹535.59

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-23.65%

1 Week

-1.52%

1 Month

-3.37%

3 Months

-11.72%

6 Months

-28.13%

1 Year

-23.02%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹699.57

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.38%

Net margin 5.78% × asset turnover 0.96x × equity multiplier 1.69x

Company Overview

Sector

Chemicals

Market Cap

₹1,604 Cr

P/E (TTM)

13.1

ROE

12.0%

Book Value

₹454.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Insecticides (i) Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Chemicals sector, at 56/100. The strongest factor is Financial Strength (100/100), while Momentum (17/100) is the weakest area to weigh before deciding. Strong 3-year EPS growth (30.9%).

TopFund Score — Fundamentals Quality

56/100 — Average

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

55

Valuation

73

Cash Flow

23

Corporate Governance

63

Momentum

17

Institutional Ownership

40

Business Quality

56

Risk & Volatility

53

Liquidity

57

From Screener.in

  • −The company has delivered a poor sales growth of 8.55% over past five years.
  • −Company has a low return on equity of 12.0% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Earnings Call Transcript for quarter and half year ended September 30, 2026

Newspaper advertisement of Unaudited Financial Results for the Second Quarter and half year ended September 30, 2026.

Audio recording of Q2 and H1 FY2027 earnings call for September 30, 2026 results available online.

Insecticides India reported Q2 FY27 revenue of Rs 686 crore and H1 FY27 PAT of Rs 100 crore.

Earning Presentation for Q2 &H1 of FY 2026-27 Results

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 696 358 272 657 627 358 359 691 638 385 426 612 686
Expenses + 614 332 264 585 538 327 330 607 548 358 401 544 594
Operating Profit 82 26 9 72 90 31 28 85 89 27 25 68 92
OPM % 12.0% 7.0% 3.3% 11.0% 14.0% 9.0% 8.0% 12.0% 14.0% 7.0% 6.0% 11.0% 13.0%
Other Income + 0 1 5 3 2 0 3 4 3 1 5 6 -1
Interest 3 3 2 2 2 1 2 4 4 5 4 5 7
Depreciation 7 7 8 7 7 8 7 7 9 9 9 10 10
Profit before tax 72 17 4 66 82 22 22 77 79 14 16 59 75
Tax % 26.0% 28.0% -106.0% 25.0% 25.0% 22.0% 37.0% 25.0% 25.0% 27.0% 27.0% 25.0% 25.0%
Net Profit + 53 12 8 49 61 17 14 58 59 10 12 44 56
EPS in Rs 18 4 3 17 21 6 5 20 20 4 4 15 19
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 20 0 -10 3 -10 0 32 5 2 8 19 -12 8

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 893 906 994 1,073 1,194 1,363 1,420 1,504 1,801 1,966 2,000 2,140 2,109
Expenses + 782 814 882 925 1,006 1,207 1,268 1,333 1,679 1,804 1,779 1,913 1,896
Operating Profit 111 92 112 148 188 156 153 171 122 162 221 227 213
OPM % 12.0% 10.0% 11.0% 14.0% 16.0% 11.0% 11.0% 11.0% 7.0% 8.0% 11.0% 11.0% 10.0%
Other Income + 0 0 7 3 1 3 -2 3 1 10 8 12 11
Interest 33 26 20 16 15 24 7 7 13 11 7 17 20
Depreciation 15 16 16 17 20 24 25 26 26 29 29 36 38
Profit before tax 64 50 82 118 153 111 120 141 84 132 193 187 165
Tax % 14.0% 21.0% 27.0% 29.0% 20.0% 22.0% 21.0% 24.0% 25.0% 23.0% 26.0% 25.0% —
Net Profit + 55 40 60 84 123 87 94 107 63 102 142 139 122
EPS in Rs 19 13 19 27 40 28 30 36 21 34 49 48 42
Dividend Payout % 0.0% 10.0% 7.0% 5.0% 3.0% 10.0% 4.0% 6.0% 14.0% 9.0% 4.0% 4.0% —
Sales growth — 1 10 8 11 14 4 6 20 9 2 7 3

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 278 388 444 527 641 711 800 850 889 982 1,056 1,191 1,291
Borrowings + 322 206 237 114 305 191 100 54 163 87 105 157 248
Other Liabilities + 308 321 277 338 388 372 505 473 615 620 709 623 661
Total Liabilities 920 936 978 1,000 1,356 1,294 1,426 1,396 1,696 1,719 1,898 2,000 2,229
Fixed Assets + 210 198 185 232 240 239 239 253 263 286 282 370 372
CWIP 38 51 58 17 19 39 59 91 123 142 161 130 159
Investments 3 3 11 17 12 12 14 16 17 23 29 29 25
Other Assets + 670 684 725 735 1,084 1,004 1,115 1,037 1,294 1,268 1,426 1,472 1,673
Total Assets 920 936 978 1,000 1,356 1,294 1,426 1,396 1,696 1,719 1,898 2,000 2,229
Equity Capital 13 21 21 21 21 21 21 20 30 30 29 29 29

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -6 86 4 182 -133 242 155 135 -11 187 93 100
Cash from Investing Activity + -34 -19 -14 -26 -49 -24 -113 9 -86 -46 -38 -86
Cash from Financing Activity + 36 -64 9 -143 172 -159 -104 -115 80 -98 -61 18
Net Cash Flow -4 4 0 13 -11 59 -61 30 -17 42 -5 31
Free Cash Flow -40 67 -10 154 -171 213 108 68 -97 143 59 8
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 1 108 19 140 -54 175 120 103 16 124 61 69

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 72.16% → 72.3%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 14.32% 14.4% 14.41% 13.36% 13.34% 13.63% 13.32% 13.69% 13.85% 13.94% 14.04% 14.01%
Promoters 72.16% 72.16% 72.16% 72.16% 72.3% 72.3% 72.3% 72.3% 72.3% 72.3% 72.3% 72.3%
FII 4.41% 4.31% 4.36% 5.43% 5.13% 4.5% 4.65% 4.51% 4.46% 4.5% 4.4% 4.44%
DII 9.12% 9.14% 9.08% 9.06% 9.24% 9.59% 9.72% 9.5% 9.4% 9.27% 9.26% 9.26%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Chemicals — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Insecticides (i) Ltd (this stock) 1,604 13.1 1.2 12.0%
Oriental Aromatics Ltd 1,596 154.0 2.38 0.5%
Bhageria Industries Ltd 1,594 14.1 2.35 7.03%
Bharat Rasayan Ltd 1,648 11.8 1.24 12.2%
Nitta Gelatin India Ltd. 1,544 12.8 2.73 21.0%
Vidhi Spclty F Ingrdnts L 1,533 25.4 4.23 15.6%
I G Petrochemicals Ltd 1,691 10.0 1.15 0.16%

Which Mutual Funds Hold Insecticides (i) Ltd?

Frequently Asked Questions about Insecticides (i) Ltd

Community Sentiment

What are other investors saying about Insecticides (i) Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.